
Visual representation of study timeline and selection process (Identification of the exposed group (individuals with PCOS/PCO Read codes) and their controls (without PCOS/PCO) matched 1:2 by age at index date, BMI and general practice)



^{*} To ensure good quality data, a patient is eligible to take part one year after the latest of the following dates: 1) registration with the general practice (registration date); 2) introduction of VISION Electronic Medical Record (VISION date); and 3) Acceptable Mortality Recording (AMR) date. AMR is an indicator when practices started to record information consistently and in a timely manner^{1,2}. One year latent period is applied to ensure there was sufficient time to record all important covariates.

Figure E.1: Visual presentation of study selection process

^{1.} Maguire A, Blak BT, Thompson M. The importance of defining periods of complete mortality reporting for research using automated data from primary care. Pharmacoepidemiol Drug Saf 2009; 18(1): 76-83.

^{2.} Horsfall L, Walters K, Petersen I. Identifying periods of acceptable computer usage in primary care research databases. Pharmacoepidemiol Drug Saf 2013; 22(1): 64-9.